<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:107.0pt;left:491.8pt;line-height:6.5pt"><i><span style="font-family:Times New Roman,serif;font-size:6.5pt">Multiple Sclerosis Journal</span></i></p>
<p style="top:120.0pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">2015, Vol. 21(12) 1485 &#x2013;1495</span></p>
<p style="top:133.0pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">DOI: 10.1177/ </span></p>
<p style="top:141.5pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">1352458515601513</span></p>
<p style="top:154.5pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">&#xa9; The Author(s), 2015.  </span></p>
<p style="top:163.0pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Reprints and permissions:  </span></p>
<p style="top:171.5pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">http://www.sagepub.co.uk/ </span></p>
<p style="top:180.0pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">journalsPermissions.nav</span></p>
<p style="top:35.6pt;left:42.5pt;line-height:10.0pt"><b><span style="font-family:DINNeuzeitGroteskStd,serif;font-size:10.0pt;color:#005337">MULTIPLE</span></b></p>
<p style="top:45.6pt;left:42.5pt;line-height:10.0pt"><b><span style="font-family:DINNeuzeitGroteskStd,serif;font-size:10.0pt;color:#005337">SCLEROSIS MSJ</span></b></p>
<p style="top:55.6pt;left:42.5pt;line-height:10.0pt"><b><span style="font-family:DINNeuzeitGroteskStd,serif;font-size:10.0pt;color:#005337">JOURNAL</span></b></p>
<p style="top:755.1pt;left:42.5pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">http://msj.sagepub.com </span></p>
<p style="top:755.1pt;left:556.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">1485</span></p>
<p style="top:543.2pt;left:42.5pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Introduction</span></b></p>
<p style="top:555.2pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Multiple sclerosis (MS) is an inflammatory disorder </span></p>
<p style="top:567.2pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">that is characterized by focal damage to white matter, </span></p>
<p style="top:579.2pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">oligodendrocyte cell death and loss of myelin. </span></p>
<p style="top:591.2pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Clinically available therapies reduce relapses but they </span></p>
<p style="top:603.2pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">do not effectively slow irreversible damage, such as </span></p>
<p style="top:615.2pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neuronal and axonal injury, which occurs during both </span></p>
<p style="top:627.2pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the early and late phases of the disease.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">1</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Cumulative </span></p>
<p style="top:639.2pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">axonal and neuronal injury is thought to be a major </span></p>
<p style="top:651.2pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">contributor to MS progression,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">2,3</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> which will eventu-</span></p>
<p style="top:663.2pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ally affect the majority of people with MS.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">4</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Methods </span></p>
<p style="top:675.2pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">that slow or stop axonal injury and brain atrophy are </span></p>
<p style="top:687.2pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">valuable therapeutic targets.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">5&#x2013;7</span></sup></p>
<p style="top:711.2pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Oxidative stress (OS), the overabundance of reactive </span></p>
<p style="top:723.2pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">oxygen species (ROS) or reactive nitrogen species </span></p>
<p style="top:543.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(RNS), is one contributor to neuronal and axonal injury </span></p>
<p style="top:555.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in MS.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">8,9</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> When there is a preponderance of ROS/RNS </span></p>
<p style="top:567.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in the brain and spinal cord that cannot be adequately </span></p>
<p style="top:579.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">eliminated by endogenous mechanisms, neural tissue </span></p>
<p style="top:591.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">becomes injured. Evidence for a role of ROS/RNS in </span></p>
<p style="top:603.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the pathology of MS is offered by the accumulation of </span></p>
<p style="top:615.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">oxidized lipids, nucleotides or proteins. Active and </span></p>
<p style="top:627.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">expanding MS lesions express increased oxidized lipid </span></p>
<p style="top:639.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and nucleotide species, especially in degenerating axons </span></p>
<p style="top:651.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and damaged oligodendrocytes.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">10,11</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Moreover, there is </span></p>
<p style="top:663.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">an upregulation of nitric oxide synthase and nicotina-</span></p>
<p style="top:675.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mide adenine dinucleotide phosphate (NADPH) oxi-</span></p>
<p style="top:687.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">dase in MS lesions,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">12,13</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> which are enzymes that produce </span></p>
<p style="top:699.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nitric oxide and superoxide, respectively. Together, </span></p>
<p style="top:711.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nitric oxide and superoxide are the important contribu-</span></p>
<p style="top:723.2pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tors to focal axonal swelling and degeneration.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">14</span></sup></p>
<p style="top:105.3pt;left:42.5pt;line-height:20.0pt"><b><span style="font-family:Times New Roman,serif;font-size:20.0pt">Over-the-counter anti-oxidant therapies for use </span></b></p>
<p style="top:129.3pt;left:42.5pt;line-height:20.0pt"><b><span style="font-family:Times New Roman,serif;font-size:20.0pt">in multiple sclerosis: A systematic review</span></b></p>
<p style="top:167.3pt;left:42.5pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Jason R. Plemel</span></b><sup><b><span style="font-family:Times New Roman,serif;font-size:6.5pt;color:#005337">*</span></b></sup><b><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">, Camille A. Juzwik</span></b><sup><b><span style="font-family:Times New Roman,serif;font-size:6.5pt;color:#005337">*</span></b></sup><b><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">, Curtis A. Benson</span></b><sup><b><span style="font-family:Times New Roman,serif;font-size:6.5pt;color:#005337">*</span></b></sup><b><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">, Michael Monks,  </span></b></p>
<p style="top:179.3pt;left:42.5pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Chelsea Harris and Michelle Ploughman</span></b></p>
<p style="top:196.1pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">*These authors contributed equally</span></p>
<p style="top:218.9pt;left:42.5pt;line-height:10.5pt"><b><i><span style="font-family:Times New Roman,serif;font-size:10.5pt;color:#005337">Abstract</span></i></b></p>
<p style="top:231.9pt;left:42.5pt;line-height:10.5pt"><b><span style="font-family:Times New Roman,serif;font-size:10.5pt">Background:</span></b><span style="font-family:Times New Roman,serif;font-size:10.5pt"> Anti-oxidant compounds that are found in over-the-counter (OTC) supplements and foods </span></p>
<p style="top:244.9pt;left:42.5pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">are gaining interest as treatments for multiple sclerosis (MS). They are widely used by patients, some-</span></p>
<p style="top:257.9pt;left:42.5pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">times without a clear evidence base.</span></p>
<p style="top:270.9pt;left:42.5pt;line-height:10.5pt"><b><span style="font-family:Times New Roman,serif;font-size:10.5pt">Objective:</span></b><span style="font-family:Times New Roman,serif;font-size:10.5pt"> We conducted a systematic review of animal and clinical research to determine the evidence </span></p>
<p style="top:283.9pt;left:42.5pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">for the benefits of OTC anti-oxidants in MS.</span></p>
<p style="top:296.9pt;left:42.5pt;line-height:10.5pt"><b><span style="font-family:Times New Roman,serif;font-size:10.5pt">Methods:</span></b><span style="font-family:Times New Roman,serif;font-size:10.5pt"> Using predefined criteria, we searched key databases. Two authors scrutinized all studies </span></p>
<p style="top:309.8pt;left:42.5pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">against inclusion/exclusion criteria, assessed study risk-of-bias and extracted results.</span></p>
<p style="top:322.8pt;left:42.5pt;line-height:10.5pt"><b><span style="font-family:Times New Roman,serif;font-size:10.5pt">Results:</span></b><span style="font-family:Times New Roman,serif;font-size:10.5pt"> Of the 3507 titles, 145 met criteria and included compounds, &#x3b1;(alpha)-lipoic acid (ALA), anti-</span></p>
<p style="top:335.8pt;left:42.5pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">oxidant vitamins, </span><i><span style="font-family:Times New Roman,serif;font-size:10.5pt">Ginkgo biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.5pt">, quercetin, resveratrol and epigallocatechin-3-gallate (ECGC). The </span></p>
<p style="top:348.8pt;left:42.5pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">strongest evidence to support OTC anti-oxidants was for compounds EGCG and ALA in animal models; </span></p>
<p style="top:361.8pt;left:42.5pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">both consistently showed anti-inflammatory/anti-oxidant effects and reduced neurological impairment. </span></p>
<p style="top:374.8pt;left:42.5pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">Only vitamin E, </span><i><span style="font-family:Times New Roman,serif;font-size:10.5pt">Ginkgo biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.5pt"> and ALA were examined for efficacy in pilot clinical trials with either </span></p>
<p style="top:387.8pt;left:42.5pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">conflicting evidence or evidence of no benefit.</span></p>
<p style="top:400.8pt;left:42.5pt;line-height:10.5pt"><b><span style="font-family:Times New Roman,serif;font-size:10.5pt">Conclusion:</span></b><span style="font-family:Times New Roman,serif;font-size:10.5pt"> OTC anti-oxidants EGCG and ALA show the most consistent benefit, however only in </span></p>
<p style="top:413.8pt;left:42.5pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">preclinical studies. There is no evidence that they alter MS relapses or progression. Future work should </span></p>
<p style="top:426.8pt;left:42.5pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">focus on testing more of these therapies for clinical efficacy before recommending them to MS patients.</span></p>
<p style="top:468.3pt;left:42.5pt;line-height:10.5pt"><b><i><span style="font-family:Times New Roman,serif;font-size:10.5pt;color:#005337">Keywords:</span></i></b><b><span style="font-family:Times New Roman,serif;font-size:10.5pt"> </span></b><span style="font-family:Times New Roman,serif;font-size:10.5pt">Alpha lipoic acid, polyphenols, </span><i><span style="font-family:Times New Roman,serif;font-size:10.5pt">Ginkgo biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.5pt">, vitamins, oxidative stress, complementary, </span></p>
<p style="top:481.3pt;left:42.5pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">alternative therapies</span></p>
<p style="top:504.3pt;left:42.5pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">Date received: 4 February 2015; revised: 11 July 2015; accepted: 27 July 2015</span></p>
<p style="top:220.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Correspondence to: </span></p>
<p style="top:228.7pt;left:491.8pt;line-height:6.5pt"><b><span style="font-family:Times New Roman,serif;font-size:6.5pt;color:#005337">Dr Michelle Ploughman</span></b><span style="font-family:Times New Roman,serif;font-size:6.5pt"> </span></p>
<p style="top:236.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Recovery &amp; Performance </span></p>
<p style="top:244.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Laboratory, Faculty of </span></p>
<p style="top:252.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Medicine, Memorial </span></p>
<p style="top:260.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">University, Room 400, L.A. </span></p>
<p style="top:268.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Miller Centre, 100 Forest </span></p>
<p style="top:276.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Rd., St. John&#x2019;s NL A1A 1E5, </span></p>
<p style="top:284.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Canada. </span></p>
<p style="top:292.7pt;left:491.8pt;line-height:6.5pt"><b><span style="font-family:Times New Roman,serif;font-size:6.5pt;color:#005337">michelle.ploughman@med.</span></b></p>
<p style="top:300.7pt;left:491.8pt;line-height:6.5pt"><b><span style="font-family:Times New Roman,serif;font-size:6.5pt;color:#005337">mun.ca</span></b></p>
<p style="top:311.7pt;left:491.8pt;line-height:6.5pt"><b><span style="font-family:Times New Roman,serif;font-size:6.5pt">Jason R. Plemel</span></b><span style="font-family:Times New Roman,serif;font-size:6.5pt"> </span></p>
<p style="top:319.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Department of Clinical </span></p>
<p style="top:327.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Neurosciences and the </span></p>
<p style="top:335.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Hotchkiss Brain Institute, </span></p>
<p style="top:343.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">University of Calgary, </span></p>
<p style="top:351.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Canada</span></p>
<p style="top:362.7pt;left:491.8pt;line-height:6.5pt"><b><span style="font-family:Times New Roman,serif;font-size:6.5pt">Camille A. Juzwik</span></b><span style="font-family:Times New Roman,serif;font-size:6.5pt"> </span></p>
<p style="top:370.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Department of Neurology </span></p>
<p style="top:378.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">and Neurosurgery, Montr&#xe9;al </span></p>
<p style="top:386.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Neurological Institute, </span></p>
<p style="top:394.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Canada</span></p>
<p style="top:405.7pt;left:491.8pt;line-height:6.5pt"><b><span style="font-family:Times New Roman,serif;font-size:6.5pt">Curtis A. Benson</span></b><span style="font-family:Times New Roman,serif;font-size:6.5pt"> </span></p>
<p style="top:413.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Neuroscience and Mental </span></p>
<p style="top:421.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Health Institute, University of </span></p>
<p style="top:429.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Alberta, Canada</span></p>
<p style="top:440.7pt;left:491.8pt;line-height:6.5pt"><b><span style="font-family:Times New Roman,serif;font-size:6.5pt">Michael Monks</span></b><span style="font-family:Times New Roman,serif;font-size:6.5pt">  </span></p>
<p style="top:448.7pt;left:491.8pt;line-height:6.5pt"><b><span style="font-family:Times New Roman,serif;font-size:6.5pt">Chelsea Harris</span></b><span style="font-family:Times New Roman,serif;font-size:6.5pt">  </span></p>
<p style="top:456.7pt;left:491.8pt;line-height:6.5pt"><b><span style="font-family:Times New Roman,serif;font-size:6.5pt">Michelle Ploughman</span></b><span style="font-family:Times New Roman,serif;font-size:6.5pt"> </span></p>
<p style="top:464.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Recovery &amp; Performance </span></p>
<p style="top:472.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Laboratory, Memorial </span></p>
<p style="top:480.7pt;left:491.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">University, Canada</span></p>
<p style="top:2.4pt;left:7.6pt;line-height:9.5pt"><span style="font-family:Times New Roman,serif;font-size:9.5pt;color:#ffffff">601513</span><span style="font-family:Times New Roman,serif;font-size:1.0pt;color:#ffffff"> MSJ0010.1177/1352458515601513Multiple Sclerosis JournalPlemel et al.</span></p>
<p style="top:10.2pt;left:7.6pt;line-height:1.0pt"><span style="font-family:Times New Roman,serif;font-size:1.0pt;color:#ffffff">research-article2015</span></p>
<p style="top:81.6pt;left:42.5pt;line-height:10.5pt"><i><span style="font-family:Times New Roman,serif;font-size:10.5pt;color:#005337">Topical Review</span></i></p>
<img style="position:absolute;transform:matrix(.374269,0,-0,.3851852,-38,-6.6653645)" src="data:image/png;base64,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">


<p style="top:34.3pt;left:25.5pt;line-height:10.5pt"><i><span style="font-family:Times New Roman,serif;font-size:10.5pt">Multiple Sclerosis Journal</span></i><span style="font-family:Times New Roman,serif;font-size:10.5pt"> 21(12)</span></p>
<p style="top:755.1pt;left:25.5pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">1486 </span></p>
<p style="top:755.1pt;left:492.1pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">http://msj.sagepub.com</span></p>
<p style="top:258.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Anti-oxidant drug therapies, diets, and supplements, </span></p>
<p style="top:270.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">purported to counteract ROS and RNS cascades, are </span></p>
<p style="top:282.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">available as over-the-counter (OTC) remedies yet </span></p>
<p style="top:294.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">their benefits have not been proven. Most people with </span></p>
<p style="top:306.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">MS reporting using an OTC supplement despite the </span></p>
<p style="top:318.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lack of a clear evidence base.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">15</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> We undertook this </span></p>
<p style="top:330.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">study to systematically and rigorously examine current </span></p>
<p style="top:342.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">research findings on the effects of OTC anti-oxidant </span></p>
<p style="top:354.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">supplements in animal models and clinical trials in </span></p>
<p style="top:366.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">MS. Our aim was to translate research findings to MS </span></p>
<p style="top:378.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">clinicians and to identify areas for future research.</span></p>
<p style="top:414.0pt;left:113.4pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Methods</span></b></p>
<p style="top:444.0pt;left:113.4pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Search strategy</span></i></p>
<p style="top:456.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">With the assistance of a librarian expert in sys- </span></p>
<p style="top:468.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tematic reviews and using predefined search terms </span></p>
<p style="top:480.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(Table 1), we searched PubMed, CINAHL, PsychInfo, the </span></p>
<p style="top:492.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Cochrane Library, and the Central Register of Controlled </span></p>
<p style="top:504.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Clinical Trials, including all years up to 1 October 2013 </span></p>
<p style="top:516.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(English language only). Clinical studies were included </span></p>
<p style="top:528.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">if the participants had MS or the biological products </span></p>
<p style="top:540.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tested were from people with MS. Animal studies were </span></p>
<p style="top:552.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">included if a disease, similar to MS, was induced in ani-</span></p>
<p style="top:564.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mals and included at least behavioral findings.</span></p>
<p style="top:600.0pt;left:113.4pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Data extraction and synthesis</span></i></p>
<p style="top:612.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Following Preferred Reporting Items for Systematic </span></p>
<p style="top:624.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Reviews and Meta-Analyses (PRISMA) guidelines,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">16</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:636.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and after duplicates were removed, we merged titles </span></p>
<p style="top:648.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">retrieved across search databases. At the title, abstract, </span></p>
<p style="top:660.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and manuscript levels of the search, two authors eval-</span></p>
<p style="top:672.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">uated inclusion status independently and if the authors </span></p>
<p style="top:684.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">disagreed, the article was included. Data extraction </span></p>
<p style="top:696.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and synthesis was conducted on manuscripts that </span></p>
<p style="top:708.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were categorized by compound tested. Reference lists </span></p>
<p style="top:720.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of included articles were hand-searched and two </span></p>
<p style="top:258.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">authors scrutinized all titles against inclusion criteria. </span></p>
<p style="top:270.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The data from all studies were extracted into article </span></p>
<p style="top:282.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">summary spreadsheets. In order to prevent inflation of </span></p>
<p style="top:294.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">findings, we required at least three studies testing a </span></p>
<p style="top:306.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">specific compound of interest in order to be included. </span></p>
<p style="top:318.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Each study was assessed for risk-of-bias: the clinical </span></p>
<p style="top:330.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies using the Cochrane Collaboration risk-of-bias </span></p>
<p style="top:342.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tool;</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">17</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and animal studies using a combination of two </span></p>
<p style="top:354.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">previously published checklists.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">18,19</span></sup></p>
<p style="top:390.0pt;left:339.1pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Results</span></b></p>
<p style="top:402.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Our review resulted in 3507 titles, of which 400 were </span></p>
<p style="top:414.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reviewed at the manuscript level (Figure 1). Although </span></p>
<p style="top:426.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">there were 12 studies examining uric acid, we did not </span></p>
<p style="top:438.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">synthesize the findings since there are several recent </span></p>
<p style="top:450.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reviews as well as a clinical trial completed.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">20&#x2013;22</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:462.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Similarly, there is a recent Cochrane review that sum-</span></p>
<p style="top:474.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">marizes the literature regarding polyunsaturated fatty </span></p>
<p style="top:486.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">acids (PUFA).</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">23</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Many compounds had fewer than three </span></p>
<p style="top:498.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies, which were below our threshold for synthesis; </span></p>
<p style="top:510.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for example, chelation, polyamines, selenium, and oth-</span></p>
<p style="top:522.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ers (Figure 1). The final research articles were grouped </span></p>
<p style="top:534.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">by category (polyphenols, anti-oxidant vitamins, alpha </span></p>
<p style="top:546.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lipoic acid (ALA), and </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Ginkgo biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">). A summary is </span></p>
<p style="top:558.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">provided describing the extent of the research evidence </span></p>
<p style="top:570.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in polyphenols (luteolin, quercetin, curcumin, EGCG, </span></p>
<p style="top:582.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and resveratrol), anti-oxidant vitamins (A, C, and E), </span></p>
<p style="top:594.0pt;left:339.1pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and ALA (Table 2). We found that evidence in </span></p>
<p style="top:606.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">animal models consistently supported the benefits of </span></p>
<p style="top:618.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">EGCG and ALA. The only evidence supporting use of </span></p>
<p style="top:630.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">OTC anti-oxidants among people with MS was in  </span></p>
<p style="top:642.0pt;left:339.1pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and ALA, and that evidence was conflicting.</span></p>
<p style="top:684.0pt;left:339.1pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Polyphenols</span></i></p>
<p style="top:696.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Polyphenols are the most abundant dietary anti- </span></p>
<p style="top:708.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">oxidants, occurring naturally in fruits, vegetables, and </span></p>
<p style="top:720.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cereals.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">24</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> They are believed to function through their </span></p>
<p style="top:71.3pt;left:113.4pt;line-height:9.0pt"><b><span style="font-family:Times New Roman,serif;font-size:9.0pt;color:#005337">Table 1.</span></b><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Search terms.</span></p>
<p style="top:90.3pt;left:119.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Area</span></p>
<p style="top:90.3pt;left:203.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Search terms</span></p>
<p style="top:108.1pt;left:119.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Pathology</span><sup><span style="font-family:Times New Roman,serif;font-size:5.8pt">*</span></sup></p>
<p style="top:108.1pt;left:203.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Multiple sclerosis, chronic neurological disease, central nervous system (CNS), inflammation, </span></p>
<p style="top:118.6pt;left:203.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">demyelination, remyelination, axonal degeneration, cortical atrophy, virus demyelination, </span></p>
<p style="top:129.1pt;left:203.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">randomized controlled trials, clinical controlled trials, animal model, model, experimental </span></p>
<p style="top:139.6pt;left:203.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">autoimmune encephalomyelitis (EAE), cuprizone, focal demyelination</span></p>
<p style="top:150.8pt;left:119.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Intervention</span><sup><span style="font-family:Times New Roman,serif;font-size:5.8pt">*</span></sup></p>
<p style="top:150.8pt;left:203.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Anti-oxidant, OS, ROS, RNS, hydroxyl radicals, peroxynitrite, superoxide, metal chelators, </span></p>
<p style="top:161.3pt;left:203.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">iron chelators, dietary intervention, diet plan, dietary supplements, dietary management, anti-</span></p>
<p style="top:171.8pt;left:203.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">inflammatory, poly-unsaturated fatty acids (PUFAs), selenium, blueberries, green tea, </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Ginkgo </span></i></p>
<p style="top:182.3pt;left:203.0pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">biloba</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> extracts, coenzyme Q10, turmeric, curcumin, vitamin C, vitamin E, vitamin A, phenolic, </span></p>
<p style="top:192.8pt;left:203.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">polyphenol, flavonoid, carotenoid</span></p>
<p style="top:209.2pt;left:119.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">* Titles were included if the title or keywords included at least one term from the &#x2018;pathology terms&#x2019; list and one term from the &#x2018;inter-</span></p>
<p style="top:218.7pt;left:123.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">vention terms&#x2019;.</span></p>


<p style="top:34.3pt;left:451.1pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">JR Plemel, CA Juzwik </span><i><span style="font-family:Times New Roman,serif;font-size:10.5pt">et al.</span></i></p>
<p style="top:755.1pt;left:42.5pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">http://msj.sagepub.com </span></p>
<p style="top:755.1pt;left:556.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">1487</span></p>
<p style="top:547.9pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">anti-oxidant and radical scavenging activities.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">25</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Our </span></p>
<p style="top:559.9pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">review included 15 studies examining five com-</span></p>
<p style="top:571.9pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pounds classified as polyphenols, where some studies </span></p>
<p style="top:583.9pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">examine more than one compound: quercetin,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">26&#x2013;29</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:595.9pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">luteolin,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">26,29,30</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> curcumin,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">29,31,32</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> resveratrol,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">33&#x2013;36</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and </span></p>
<p style="top:607.9pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">epigallocatechin-3-gallate (EGCG).</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">37&#x2013;40</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Details of the </span></p>
<p style="top:619.9pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">included studies are found in Supplementary Table 3 </span></p>
<p style="top:631.9pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and assessment of risk-of-bias in Supplementary </span></p>
<p style="top:643.9pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Figure 2(a) and (b).</span></p>
<p style="top:672.0pt;left:42.5pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Quercetin.</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> There were three animal studies examining </span></p>
<p style="top:684.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">quercetin in EAE,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">26,27,29</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and one </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">ex vivo</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> assessment </span></p>
<p style="top:696.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">from MS patients.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">28</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> When quercetin was administered </span></p>
<p style="top:708.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">by intraperitoneal (i.p.) injection, EAE severity score </span></p>
<p style="top:720.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">was less severe, which was associated with decreased </span></p>
<p style="top:552.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">immune cell infiltrates in the spinal cord.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">26,27</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> However, </span></p>
<p style="top:564.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">when administered orally, mice showed no improve-</span></p>
<p style="top:576.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ment.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">29</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> In the single clinical study, Peripheral blood </span></p>
<p style="top:588.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mononuclear cells (PBMCs) from RR-MS patients </span></p>
<p style="top:600.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and healthy controls were treated with quercetin or </span></p>
<p style="top:612.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">quercetin plus the drug interferon-&#x3b2; (IFN-&#x3b2;) to exam-</span></p>
<p style="top:624.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ine potentially synergistic effects, but nothing conclu-</span></p>
<p style="top:636.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sive can be drawn as the baseline effect of IFN-&#x3b2; alone </span></p>
<p style="top:648.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">was not included.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">28</span></sup></p>
<p style="top:672.0pt;left:268.2pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Luteolin.</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> In the three studies (two in animals and one </span></p>
<p style="top:684.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">clinical study) examining luteolin, we see conflicting </span></p>
<p style="top:696.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">results.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">26,29,30</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> In EAE animals, luteolin either showed no </span></p>
<p style="top:708.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improvement</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">29</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> or a decrease in disease severity;</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">26</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and </span></p>
<p style="top:720.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">an </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">ex vivo</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> assessment of PBMCs from RR-MS patients </span></p>
<img style="position:absolute;transform:matrix(.54816988,0,-0,.54857149,8.606293,-103.75665)" src="data:image/png;base64,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">
<p style="top:493.1pt;left:42.5pt;line-height:9.0pt"><b><span style="font-family:Times New Roman,serif;font-size:9.0pt;color:#005337">Figure 1.</span></b><span style="font-family:Times New Roman,serif;font-size:9.0pt"> PRISMA diagram. Of 147 articles evaluated by group consensus, seven compounds were excluded because </span></p>
<p style="top:503.6pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">there were too few studies (&lt;3) to proceed. By consensus, we also excluded mixed diets such as the Swank diet, fatty </span></p>
<p style="top:514.1pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">acids, and products that were not available OTC.</span></p>


<p style="top:34.3pt;left:25.5pt;line-height:10.5pt"><i><span style="font-family:Times New Roman,serif;font-size:10.5pt">Multiple Sclerosis Journal</span></i><span style="font-family:Times New Roman,serif;font-size:10.5pt"> 21(12)</span></p>
<p style="top:755.1pt;left:25.5pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">1488 </span></p>
<p style="top:755.1pt;left:492.1pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">http://msj.sagepub.com</span></p>
<p style="top:722.7pt;left:215.1pt;line-height:9.0pt"><b><span style="font-family:Times New Roman,serif;font-size:9.0pt;color:#005337">Table 2.</span></b><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Summary of research evidence.</span></p>
<p style="top:599.4pt;left:234.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Luteolin</span></p>
<p style="top:551.5pt;left:234.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Quercetin</span></p>
<p style="top:493.7pt;left:234.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Curcumin</span></p>
<p style="top:437.7pt;left:234.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EGCG</span></p>
<p style="top:386.4pt;left:234.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Resveratrol</span></p>
<p style="top:328.8pt;left:234.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Vitamin A</span></p>
<p style="top:276.2pt;left:234.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Vitamin C</span></p>
<p style="top:215.8pt;left:234.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Vitamin E</span></p>
<p style="top:164.2pt;left:234.1pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Ginkgo </span></i></p>
<p style="top:164.2pt;left:244.6pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">biloba</span></i></p>
<p style="top:120.8pt;left:234.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Alpha lipoic </span></p>
<p style="top:120.8pt;left:244.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">acid (ALA)</span></p>
<p style="top:599.4pt;left:262.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Broccoli</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">*</span></p>
<p style="top:551.5pt;left:262.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Cranberries</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">*</span></p>
<p style="top:493.7pt;left:262.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Tumeric</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">*</span></p>
<p style="top:437.7pt;left:262.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Green tea</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">*</span></p>
<p style="top:386.4pt;left:262.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Red grapes</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">*</span></p>
<p style="top:328.8pt;left:262.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Spinach</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">*</span></p>
<p style="top:276.2pt;left:262.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Red pepper</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">*</span></p>
<p style="top:215.8pt;left:262.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Almonds</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">*</span></p>
<p style="top:164.2pt;left:262.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Extract</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">*</span></p>
<p style="top:120.8pt;left:262.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Organ meats</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">*</span></p>
<p style="top:716.7pt;left:274.8pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Animal models</span></p>
<p style="top:716.7pt;left:287.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:706.0pt;left:287.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Anti-inflammatory/anti-</span></p>
<p style="top:706.0pt;left:297.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">oxidant properties</span></p>
<p style="top:599.4pt;left:287.3pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> X</span></p>
<p style="top:551.5pt;left:287.3pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span></p>
<p style="top:493.7pt;left:287.3pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span></p>
<p style="top:437.7pt;left:287.3pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span></p>
<p style="top:386.4pt;left:287.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">X</span></p>
<p style="top:328.7pt;left:287.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:276.2pt;left:287.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:215.8pt;left:287.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:164.2pt;left:287.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:120.8pt;left:287.3pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span></p>
<p style="top:716.7pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:706.0pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Decreased damage to </span></p>
<p style="top:706.0pt;left:320.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">nervous system (e.g. </span></p>
<p style="top:706.0pt;left:331.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">relapses)</span></p>
<p style="top:599.4pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:551.5pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:493.7pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:437.7pt;left:310.3pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span></p>
<p style="top:386.4pt;left:310.3pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> X</span></p>
<p style="top:328.7pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:276.2pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:215.8pt;left:310.3pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span></p>
<p style="top:164.2pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:120.8pt;left:310.3pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span></p>
<p style="top:716.7pt;left:343.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:706.0pt;left:343.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Reduced disease severity</span></p>
<p style="top:599.4pt;left:343.8pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> X</span></p>
<p style="top:551.5pt;left:343.8pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span></p>
<p style="top:493.7pt;left:343.8pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span></p>
<p style="top:437.7pt;left:343.8pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span></p>
<p style="top:386.4pt;left:343.8pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span></p>
<p style="top:328.7pt;left:343.8pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span></p>
<p style="top:276.2pt;left:343.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">X</span></p>
<p style="top:215.8pt;left:343.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:164.2pt;left:343.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:120.8pt;left:343.8pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span></p>
<p style="top:716.7pt;left:356.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">MS patients</span></p>
<p style="top:716.7pt;left:368.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:706.0pt;left:368.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Anti-inflammatory/anti-</span></p>
<p style="top:706.0pt;left:379.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">oxidant properties</span></p>
<p style="top:599.4pt;left:368.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:551.5pt;left:368.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:493.7pt;left:368.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:437.7pt;left:368.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:386.4pt;left:368.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:328.7pt;left:368.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:276.2pt;left:368.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:215.8pt;left:368.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:164.2pt;left:368.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:120.8pt;left:368.8pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> X</span></p>
<p style="top:716.7pt;left:391.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:706.0pt;left:391.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Decreased relapses</span></p>
<p style="top:599.4pt;left:391.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:551.5pt;left:391.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:493.7pt;left:391.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:437.7pt;left:391.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:386.4pt;left:391.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:328.7pt;left:391.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:276.2pt;left:391.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:215.8pt;left:391.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:164.2pt;left:391.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:120.8pt;left:391.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:716.7pt;left:403.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:706.0pt;left:403.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Reduced disease </span></p>
<p style="top:706.0pt;left:413.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">progression</span></p>
<p style="top:599.4pt;left:403.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:551.5pt;left:403.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:493.7pt;left:403.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:437.7pt;left:403.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:386.4pt;left:403.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:328.7pt;left:403.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:276.2pt;left:403.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:215.8pt;left:403.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">X</span></p>
<p style="top:164.2pt;left:403.7pt;line-height:9.0pt"><span style="font-family:Wingdings,sans-serif;font-size:9.0pt">&#xf0fc;</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> X</span></p>
<p style="top:120.8pt;left:403.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">O</span></p>
<p style="top:717.5pt;left:430.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">* Examples of natural sources of compounds. Most studies examined in this review tested purified extracts or synthesized products. </span><span style="font-family:Wingdings,sans-serif;font-size:8.0pt">&#xf0fc;</span><span style="font-family:Times New Roman,serif;font-size:8.0pt"> evidence to support; X evidence that there is no benefit; O no </span></p>
<p style="top:713.5pt;left:440.1pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">evidence.</span></p>


<p style="top:34.3pt;left:451.1pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">JR Plemel, CA Juzwik </span><i><span style="font-family:Times New Roman,serif;font-size:10.5pt">et al.</span></i></p>
<p style="top:755.1pt;left:42.5pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">http://msj.sagepub.com </span></p>
<p style="top:755.1pt;left:556.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">1489</span></p>
<p style="top:72.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treated with luteolin plus IFN-&#x3b2; provide no conclusive </span></p>
<p style="top:84.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">data as a critical control group was missing.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">30</span></sup></p>
<p style="top:108.0pt;left:42.5pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Curcumin.</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Curcumin is the main ingredient of tur-</span></p>
<p style="top:120.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">meric and a lipophilic compound that crosses mem-</span></p>
<p style="top:132.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">branes easily, making it a promising oral therapy.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">41</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:144.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The three studies reviewed all employed animal mod-</span></p>
<p style="top:156.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">els that showed consistent anti-inflammatory bene-</span></p>
<p style="top:168.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">fits.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">29,31,32</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> It decreased the T cell production of </span></p>
<p style="top:180.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">IFN-&#x3b3;;</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">29</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> prevented the differentiation of T helper 1 </span></p>
<p style="top:192.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(Th1) cells;</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">31</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and decreased the amount of Th17- </span></p>
<p style="top:204.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">differentiated cells.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">32</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> As the included studies adminis-</span></p>
<p style="top:216.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tered curcumin before the onset of clinical symptoms, </span></p>
<p style="top:228.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">only preventative effects were assessed.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">29,31,32</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> One </span></p>
<p style="top:240.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">clinical trial examining curcumin as an adjunct ther-</span></p>
<p style="top:252.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">apy to IFN-&#x3b2;1a is in recruitment phase (clinicaltrials.</span></p>
<p style="top:264.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">gov, NCT01514370).</span></p>
<p style="top:288.0pt;left:42.5pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">EGCG.</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> EGCG is the most abundant of the biologi-</span></p>
<p style="top:300.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cally active catechins present in green tea. Four stud-</span></p>
<p style="top:312.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ies examined the ability of purified EGCG (95%) to </span></p>
<p style="top:324.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">decrease the severity of EAE disease (Table 2 and </span></p>
<p style="top:336.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Supplementary Table 3).</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">37&#x2013;40</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> EGCG-fed animals con-</span></p>
<p style="top:348.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sistently showed decreased severity scores compared </span></p>
<p style="top:360.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to control-fed animals, which was associated with </span></p>
<p style="top:372.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">suppressed immune cell infiltrates,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">37&#x2013;39</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> decreased </span></p>
<p style="top:384.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">demyelination in the spinal cord,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">39,42</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and a decreased </span></p>
<p style="top:396.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">production of inflammatory cytokines that promote </span></p>
<p style="top:408.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Th1 and Th17 differentiation.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">37,39,40</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Furthermore, </span></p>
<p style="top:420.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">EGCG enhanced the viability and outgrowth of hip-</span></p>
<p style="top:432.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pocampal cells in vitro.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">37,38</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> To date, there are six </span></p>
<p style="top:444.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ongoing trials investigating EGCG as an adjunct ther-</span></p>
<p style="top:456.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">apy in MS listed on clinicaltrials.gov (NCT00525668, </span></p>
<p style="top:468.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">NCT02011451, </span></p>
<p style="top:468.0pt;left:117.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">NCT00799890, </span></p>
<p style="top:468.0pt;left:193.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">NCT00836719, </span></p>
<p style="top:480.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">NCT01451723, and NCT01417312). Most of these </span></p>
<p style="top:492.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies focus on the safety and the neuroprotective </span></p>
<p style="top:504.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ability of EGCG by assessing levels of neuronal </span></p>
<p style="top:516.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">marker </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">N</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">-acetyl aspartate, used to identify the num-</span></p>
<p style="top:528.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ber of neurons and their metabolism.</span></p>
<p style="top:552.0pt;left:42.5pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Resveratrol.</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Resveratrol is found predominantly in </span></p>
<p style="top:564.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">grapes and red wine.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">43</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> It is known to have poor bio-</span></p>
<p style="top:576.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">availability, so most studies administer SRT501, a </span></p>
<p style="top:588.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pharmaceutical formulation of resveratrol that has </span></p>
<p style="top:600.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">enhanced systemic absorption.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">33,43</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> In four studies </span></p>
<p style="top:612.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reviewed (all in animal models), both resveratrol </span></p>
<p style="top:624.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and SRT501 consistently decreased EAE sever-</span></p>
<p style="top:636.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ity,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">33&#x2013;36</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> which coincided with reduced optic nerve </span></p>
<p style="top:648.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">damage and prevention of retinal ganglion cell </span></p>
<p style="top:660.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">loss.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">33,35</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Resveratrol did not alter the levels of infil-</span></p>
<p style="top:672.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">trating immune cells into the spinal cord of EAE </span></p>
<p style="top:684.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">animals, suggesting it functions through a neuropro-</span></p>
<p style="top:696.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tective mechanism;</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">33&#x2013;35</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> though one group reported </span></p>
<p style="top:708.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">decreased levels of peripheral pro-inflammatory </span></p>
<p style="top:720.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cytokines.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">36</span></sup></p>
<p style="top:72.0pt;left:268.2pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Anti-oxidant vitamins</span></i></p>
<p style="top:84.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Vitamins A (&#x3b2;-carotene and retinol), C (ascorbic acid) </span></p>
<p style="top:96.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and E (&#x3b1;-tocopherol), having anti-oxidant properties, </span></p>
<p style="top:108.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were examined in 13 studies (animal models </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">n</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> = 4; </span></p>
<p style="top:120.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">clinical </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">n</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> = 7; population wide </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">n</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> = 2).</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">44&#x2013;56</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Details of the </span></p>
<p style="top:132.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">included studies are found in Supplementary Table 4 </span></p>
<p style="top:144.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and risk-of-bias in Supplementary Figure 3(a) and (b).</span></p>
<p style="top:168.0pt;left:268.2pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Vitamin A.</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> There was a single animal study</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">55</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and two </span></p>
<p style="top:180.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">small clinical studies from the same cohort examining </span></p>
<p style="top:192.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">vitamin A.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">45,46</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Treatment of vitamin A following EAE </span></p>
<p style="top:204.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">increased the number of animals without EAE symp-</span></p>
<p style="top:216.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">toms.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">55</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> The two clinical studies were small, with </span></p>
<p style="top:228.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">fewer than 20 subjects treated for 6 months with </span></p>
<p style="top:240.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">25,000 IU vitamin A, finding decreased peripheral </span></p>
<p style="top:252.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">immune cell proliferation, but only when cells were </span></p>
<p style="top:264.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cultured with fetal calf serum and not when cultured </span></p>
<p style="top:276.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with human serum.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">46</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> In the same cohort, vitamin A </span></p>
<p style="top:288.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treatment increased the inflammatory marker C-reac-</span></p>
<p style="top:300.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tive protein indicating that vitamin A may also induce </span></p>
<p style="top:312.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">certain aspects of inflammation.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">45</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> There is currently a </span></p>
<p style="top:324.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">registered clinical trial of vitamin A (clinicaltrials.gov </span></p>
<p style="top:336.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">01225289).</span></p>
<p style="top:360.0pt;left:268.2pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Vitamin E.</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Vitamin E is a group of fat-soluble anti-</span></p>
<p style="top:372.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">oxidants that include tocotrienols and tocopherols.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">57</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:384.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Vitamin E can decrease protein kinase C, an impor-</span></p>
<p style="top:396.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tant cellular signaling molecule;</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">58</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> it can also regulate </span></p>
<p style="top:408.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the inflammatory arachadonic acid cascade by </span></p>
<p style="top:420.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">increasing cytosolic phospholipase A2 and cyclooxy-</span></p>
<p style="top:432.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">genase activities.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">59</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> In the animal studies, vitamin E </span></p>
<p style="top:444.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">either protected myelin or promoted myelin regenera-</span></p>
<p style="top:456.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">44,53</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> In a small cohort of people with MS, nine </span></p>
<p style="top:468.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">subjects treated for 30 months, vitamin E alone did </span></p>
<p style="top:480.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">not decrease annual relapse rate.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">50</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> However, whether </span></p>
<p style="top:492.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">annual relapse rate meaningfully captures the protec-</span></p>
<p style="top:504.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tive effects of an anti-oxidant therapy is unclear. No </span></p>
<p style="top:516.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies examined measures of brain atrophy or lesion </span></p>
<p style="top:528.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">accumulation.</span></p>
<p style="top:552.0pt;left:268.2pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Vitamin combinations.</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> We found five clinical studies </span></p>
<p style="top:564.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">that tested anti-oxidant combinations including vita-</span></p>
<p style="top:576.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mins A, C, or E</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">47&#x2013;50,52</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> (Supplementary Table 4). In </span></p>
<p style="top:588.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">one small clinical study (9&#x2013;12 participants per treat-</span></p>
<p style="top:600.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ment arm), a mixture of several PUFAs, monosatu-</span></p>
<p style="top:612.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rated fatty acids, and saturated fatty acids along with </span></p>
<p style="top:624.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">vitamin E and vitamin A significantly reduced relapse </span></p>
<p style="top:636.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rate compared to control.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">50</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> The authors reported that </span></p>
<p style="top:648.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">vitamin E was a necessary component in this combi-</span></p>
<p style="top:660.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nation; however, it is difficult to draw definitive con-</span></p>
<p style="top:672.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">clusions. In population studies it was found that that </span></p>
<p style="top:684.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the levels of vitamin intake were not associated with </span></p>
<p style="top:696.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">increased risk of MS or disease progression when </span></p>
<p style="top:708.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">adjusted for age, time period, latitude of birthplace, </span></p>
<p style="top:720.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">smoking, and total energy.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">51,56</span></sup></p>


<p style="top:34.3pt;left:25.5pt;line-height:10.5pt"><i><span style="font-family:Times New Roman,serif;font-size:10.5pt">Multiple Sclerosis Journal</span></i><span style="font-family:Times New Roman,serif;font-size:10.5pt"> 21(12)</span></p>
<p style="top:755.1pt;left:25.5pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">1490 </span></p>
<p style="top:755.1pt;left:492.1pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">http://msj.sagepub.com</span></p>
<p style="top:72.0pt;left:113.4pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Alpha lipoic acid (ALA)</span></i></p>
<p style="top:84.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Found in very small amounts in foods such as organ </span></p>
<p style="top:96.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">meats, spinach, and broccoli, ALA is synthesized in </span></p>
<p style="top:108.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the liver and is considered to be a naturally-occurring </span></p>
<p style="top:120.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">anti-oxidant.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">60</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> ALA is a direct scavenger of free radi-</span></p>
<p style="top:132.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cals and acts indirectly as a metal chelator thereby </span></p>
<p style="top:144.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lessening free-radical damage.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">61</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Of the 12 studies </span></p>
<p style="top:156.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">included in this review, one reported findings in both </span></p>
<p style="top:168.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">humans and animals</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">62</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and four examined the effects </span></p>
<p style="top:180.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of ALA supplements in people with MS or their blood </span></p>
<p style="top:192.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">products from two samples of patients.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">62&#x2013;65</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> The </span></p>
<p style="top:204.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">remaining preclinical studies utilized the EAE rodent </span></p>
<p style="top:216.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">model.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">42,62,66&#x2013;71</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Detailed information is found in </span></p>
<p style="top:228.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Supplementary Table 5 and risk-of-bias assessments </span></p>
<p style="top:240.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in Supplementary Figure 4(a) and (b).</span></p>
<p style="top:264.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In terms of the effects of ALA on anti-oxidant/inflam-</span></p>
<p style="top:276.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">matory mediators, peripheral T cell activity in ALA-</span></p>
<p style="top:288.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">specific studies showed conflicting results.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">42,69</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:300.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Marracci et al. reported no effect of ALA on pro-</span></p>
<p style="top:312.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">inflammatory T cells</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">69</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> while Wang et al. reported </span></p>
<p style="top:324.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">suppression of CD</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">+</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> T cells obtained from ALA-</span></p>
<p style="top:336.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treated animals.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">42</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> In five studies there was a consist-</span></p>
<p style="top:348.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ent reduction in T cell infiltration into the CNS with </span></p>
<p style="top:360.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ALA treatment: spinal cord,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">42,67,69,71</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> optic nerve,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">66</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and </span></p>
<p style="top:372.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cerebellum.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">42,71</span></sup></p>
<p style="top:396.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The six studies examining the effects of ALA on </span></p>
<p style="top:408.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mediators of inflammation, such as matrix metal-</span></p>
<p style="top:420.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lopedtidase-9 (MMP-9) or soluble cell adhesion mol-</span></p>
<p style="top:432.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ecule (ICAM), in animal models</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">42,67,70</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and people </span></p>
<p style="top:444.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with MS,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">63,64,72</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> reported varying results. In serum </span></p>
<p style="top:456.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">obtained from people with MS, 1200 mg LA adminis-</span></p>
<p style="top:468.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tered daily for 14 days did not change serum levels of </span></p>
<p style="top:480.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">MMP-9, TIMP-1, or soluble cell adhesion molecule </span></p>
<p style="top:492.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(ICAM).</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">72</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> However, Khalili and group reported sig-</span></p>
<p style="top:504.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nificant reductions in pro-inflammatory markers  </span></p>
<p style="top:516.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">IFN-&#x3b3;, ICAM-1, TGF-&#x3b2;, and IL-4 after 12 weeks of </span></p>
<p style="top:528.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treatment.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">64</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Studies in animal models showed more </span></p>
<p style="top:540.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">consistent beneficial findings. ALA treatment reduced </span></p>
<p style="top:552.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">immunostimulators </span></p>
<p style="top:552.0pt;left:202.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">MMP, </span></p>
<p style="top:552.0pt;left:237.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">IFN-&#x3b3;, </span></p>
<p style="top:552.0pt;left:274.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and </span></p>
<p style="top:552.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">IL-4;</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">70</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:564.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">increased endogenous PPAR-&#x3b3;, which acts to counter-</span></p>
<p style="top:576.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">act OS;</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">42</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and reduced expression of ICAM in spinal </span></p>
<p style="top:588.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cord tissue.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">67</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Two animal studies reported dose-</span></p>
<p style="top:600.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">dependent effects of ALA, with higher dosages (100 </span></p>
<p style="top:612.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">&#xb5;g/ml versus 25 &#xb5;g/ml) being more beneficial and </span></p>
<p style="top:624.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">oral ingestion being less effective than injection.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">67,70</span></sup></p>
<p style="top:648.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Effects of ALA on recovery and repair were evaluated </span></p>
<p style="top:660.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in two ways: quantification of demyelination and </span></p>
<p style="top:672.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">axonal injury,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">66,69,70</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and behavioral/clinical neurologi-</span></p>
<p style="top:684.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cal impairment score. The three studies examining the </span></p>
<p style="top:696.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">effects of ALA on demyelination and axonal damage </span></p>
<p style="top:708.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in optic nerve, spinal cord, and brain consistently </span></p>
<p style="top:720.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">showed that ALA-treated EAE animals had reduced </span></p>
<p style="top:72.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">damage in the CNS,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">66,69,70</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> which was dependent on </span></p>
<p style="top:84.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">timing and route of administration. ALA administered </span></p>
<p style="top:96.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">by i.p. injection seven days or directly following </span></p>
<p style="top:108.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">immunization protected axons from demyelination </span></p>
<p style="top:120.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and damage.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">66,69,70</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Delayed ALA administration </span></p>
<p style="top:132.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reduced damage to optic nerve but not as robustly as </span></p>
<p style="top:144.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">immediate treatment.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">66</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Oral administration was only </span></p>
<p style="top:156.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">protective when instituted immediately, but not </span></p>
<p style="top:168.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">delayed, following EAE immunization.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">70</span></sup></p>
<p style="top:192.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">All eight studies examining the behavioral effects of </span></p>
<p style="top:204.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ALA in the EAE model showed reduced disease sever-</span></p>
<p style="top:216.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ity in ALA-treated animals.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">42,62,66&#x2013;71</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> There was no </span></p>
<p style="top:228.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">change in Expanded Disease Severity Scale (EDSS) </span></p>
<p style="top:240.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">score in the five studies among people with MS, </span></p>
<p style="top:252.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">although the longest intervention was only 12 </span></p>
<p style="top:264.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">weeks.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">64,65</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Four animal studies showed both dosage </span></p>
<p style="top:276.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and timing effects: low dosages of less than 10 mg/kg/</span></p>
<p style="top:288.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">day,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">69,71</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> or delayed dosage</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">70</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> were of minimal benefit. </span></p>
<p style="top:300.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">However, one study showed that both early and late </span></p>
<p style="top:312.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">administration of ALA abolished the EAE-related </span></p>
<p style="top:324.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">impairment during the 24 day length of the experi-</span></p>
<p style="top:336.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ment.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">66</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Yadav and group reported that EAE-related </span></p>
<p style="top:348.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">impairment was correlated with serum levels of ALA </span></p>
<p style="top:360.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in EAE animals.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">62</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Importantly, two studies showed that </span></p>
<p style="top:372.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">when ALA treatment is halted, impairments return.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">68,69</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:384.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Study durations in EAE models were less than 40 days </span></p>
<p style="top:396.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">so the long-term benefits are unknown. Furthermore, </span></p>
<p style="top:408.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the effects of ALA on MS progression, relapse, or </span></p>
<p style="top:420.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">recovery have not been tested in people with MS, </span></p>
<p style="top:432.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">although several trials are posted in clinicaltrials.gov </span></p>
<p style="top:444.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(02133664, 00676156, 01188811).</span></p>
<p style="top:468.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In all except one study</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">70</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> in animal models ALA was </span></p>
<p style="top:480.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">delivered by injection. When comparing injection of </span></p>
<p style="top:492.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ALA to delivery in drinking water, injection was more </span></p>
<p style="top:504.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">effective at reducing severity of disease and indicators of </span></p>
<p style="top:516.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">inflammation. In humans, ALA was provided orally in </span></p>
<p style="top:528.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pill form and the most common side effects were gastro-</span></p>
<p style="top:540.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">intestinal upset, malodorous urine, and rash.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">72</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> In people </span></p>
<p style="top:552.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with MS, there was wide variability in absorption and </span></p>
<p style="top:564.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">clearance of ALA between individuals.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">62</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Furthermore, </span></p>
<p style="top:576.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ALA obtained from different suppliers had different </span></p>
<p style="top:588.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rates of metabolism.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">62,72</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> These findings make it difficult </span></p>
<p style="top:600.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to know how much ALA dosage is required in humans.</span></p>
<p style="top:636.0pt;left:339.1pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Ginkgo biloba</span></i></p>
<p style="top:648.0pt;left:339.1pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Ginkgo biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> (</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">) extract is obtained from  </span></p>
<p style="top:660.0pt;left:339.1pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> tree leaves, and the commercially available </span></p>
<p style="top:672.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">products contain a mixture of biologically active </span></p>
<p style="top:684.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">compounds.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">73</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> The percentage of each compound </span></p>
<p style="top:696.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">within a </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> extract varies between suppliers; </span></p>
<p style="top:708.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">however, the most common research formulation is </span></p>
<p style="top:720.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">EGb-761, which contains approximately 24% flavone </span></p>


<p style="top:34.3pt;left:451.1pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">JR Plemel, CA Juzwik </span><i><span style="font-family:Times New Roman,serif;font-size:10.5pt">et al.</span></i></p>
<p style="top:755.1pt;left:42.5pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">http://msj.sagepub.com </span></p>
<p style="top:755.1pt;left:556.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">1491</span></p>
<p style="top:72.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">glycosides, 7% proanthocyanidins, and 6% terpene </span></p>
<p style="top:84.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lactones.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">73</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Our search revealed five studies examin-</span></p>
<p style="top:96.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ing </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> in MS, all of which were clinical trials </span></p>
<p style="top:108.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">focusing on cognitive outcomes. Our search revealed </span></p>
<p style="top:120.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">no preclinical trials in animal models of MS. Three of </span></p>
<p style="top:132.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the clinical trials were placebo-controlled, adminis-</span></p>
<p style="top:144.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tering 240 mg of </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> daily,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">74&#x2013;76</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and two of these </span></p>
<p style="top:156.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were from the same research group, in which a small </span></p>
<p style="top:168.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">study was followed by a larger trial.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">75,76</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> One open-</span></p>
<p style="top:180.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">label trial was conducted using a dose of 240 mg per </span></p>
<p style="top:192.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">day; however, one participant received a dose of 120 </span></p>
<p style="top:204.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mg due to a history of gastritis.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">77</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Lastly, one paper </span></p>
<p style="top:216.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reanalysed data from a previously conducted placebo-</span></p>
<p style="top:228.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">controlled study.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">78</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> All of these studies used commer-</span></p>
<p style="top:240.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cially available </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">, but only two used the </span></p>
<p style="top:252.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">EGb-761 formulation.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">74,75</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Details of the included </span></p>
<p style="top:264.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies are found in Supplementary Table 4, and risk-</span></p>
<p style="top:276.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of-bias is outlined in Supplementary Figure 5.</span></p>
<p style="top:300.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Four of the clinical studies reviewed examined the </span></p>
<p style="top:312.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">effects of </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> on cognitive impairment in MS with </span></p>
<p style="top:324.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">between 12 and 30 subjects in the treatment groups. </span></p>
<p style="top:336.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">These studies used different cognitive assessment tools, </span></p>
<p style="top:348.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">making it difficult to compare results. In an eight week </span></p>
<p style="top:360.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">open-label trial, MS subjects had significant improve-</span></p>
<p style="top:372.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ment on the Wechsler memory test after treatment.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">77</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> A </span></p>
<p style="top:384.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">placebo-controlled study conducted by Lovera et al. </span></p>
<p style="top:396.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">demonstrated that eight weeks of </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> treatment </span></p>
<p style="top:408.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improved scores on the Stroop memory test, indicating </span></p>
<p style="top:420.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">increased cognitive flexibility.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">76</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Using data derived </span></p>
<p style="top:432.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">from their 2006 clinic study, Diamond and group </span></p>
<p style="top:444.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reported that the </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> treated group had enhanced </span></p>
<p style="top:456.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">processing speed on the Visual Threshold Serial </span></p>
<p style="top:468.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Addition Test and emitted less verbal intrusions on the </span></p>
<p style="top:480.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">California Verbal Learning Test compared to a placebo </span></p>
<p style="top:492.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">group.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">78</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> However the largest study examining </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:504.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in 120 persons with MS with 61 randomized to </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. </span></i></p>
<p style="top:516.0pt;left:42.5pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> failed to show any benefit on cognitive func-</span></p>
<p style="top:528.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">75</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Despite minimal effects on impairment or disa-</span></p>
<p style="top:540.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">bility, two studies reported that </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> improved </span></p>
<p style="top:552.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">self-reported symptoms and quality of life.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">74,75,78</span></sup></p>
<p style="top:576.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">All of the studies included in this review studied the </span></p>
<p style="top:588.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">effects of </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> administered orally in capsule, 240 </span></p>
<p style="top:600.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mg per day divided in either 2 or 4 doses, though the </span></p>
<p style="top:612.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">commercial sources of the </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> extract varied </span></p>
<p style="top:624.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">between studies. </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> was well tolerated in most </span></p>
<p style="top:636.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cases. In one study a few participants reported mild </span></p>
<p style="top:648.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nausea.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">77</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> No severe adverse events related to </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:660.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were observed during the trials reviewed.</span></p>
<p style="top:696.0pt;left:42.5pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Discussion</span></b></p>
<p style="top:708.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In an effort to combat the OS associated with injury in </span></p>
<p style="top:720.0pt;left:42.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">MS, researchers are exploring anti-oxidant therapies </span></p>
<p style="top:72.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to reduce MS pathology. Our review focused on a  </span></p>
<p style="top:84.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">subset of this research: readily-available dietary anti-</span></p>
<p style="top:96.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">oxidant compounds available OTC. We did not include </span></p>
<p style="top:108.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">compounds that were examined in fewer than three </span></p>
<p style="top:120.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies such as chelation, glucosamine, selenium, and </span></p>
<p style="top:132.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">others. We also did not review compounds that had </span></p>
<p style="top:144.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">already been subjected to rigorous review and synthe-</span></p>
<p style="top:156.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sis: uric acid</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">20&#x2013;22</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> or PUFAs.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">23</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> The largest body of </span></p>
<p style="top:168.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">research examined ALA (12 studies) and </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> (5 </span></p>
<p style="top:180.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies), with the remaining compounds having fewer </span></p>
<p style="top:192.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">than four peer-reviewed studies. Only vitamin E, </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. </span></i></p>
<p style="top:204.0pt;left:268.2pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">, and ALA were examined in people with MS </span></p>
<p style="top:216.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with either conflicting evidence or evidence of no ben-</span></p>
<p style="top:228.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">efit (Table 2). The strongest evidence to support OTC </span></p>
<p style="top:240.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">anti-oxidants was for compounds EGCG and ALA in </span></p>
<p style="top:252.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">animal models; both compounds consistently showed </span></p>
<p style="top:264.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">anti-inflammatory/anti-oxidant </span></p>
<p style="top:264.0pt;left:402.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">effects, </span></p>
<p style="top:264.0pt;left:442.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">decreased </span></p>
<p style="top:276.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">damage to the nervous system along with reduced neu-</span></p>
<p style="top:288.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rological impairment (Table 2).</span></p>
<p style="top:324.0pt;left:268.2pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Optimal outcomes to assess the benefits of anti-</span></i></p>
<p style="top:336.0pt;left:268.2pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">oxidants</span></i></p>
<p style="top:348.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">There was a paucity of mechanistic outcomes in the </span></p>
<p style="top:360.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies included in this review. We found the reduc-</span></p>
<p style="top:372.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion of pro-inflammatory markers as a common fea-</span></p>
<p style="top:384.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ture among animal studies, but the direct cause of the </span></p>
<p style="top:396.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reduced inflammation was more often undetermined. </span></p>
<p style="top:408.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Furthermore, considering that OTC anti-oxidants are </span></p>
<p style="top:420.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">purported to provide neuroprotection and repair, there </span></p>
<p style="top:432.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were no studies that examined longer term outcomes </span></p>
<p style="top:444.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">such as reduced lesion accumulation or disability pro-</span></p>
<p style="top:456.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">gression. With the ongoing degeneration that is asso-</span></p>
<p style="top:468.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ciated with progressive MS and the presence of OS at </span></p>
<p style="top:480.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sites of degeneration,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">2,8,9,79,80</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> determining the utility </span></p>
<p style="top:492.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of anti-oxidant therapies to protect neural tissue or </span></p>
<p style="top:504.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">promote repair is a major research gap. In this review, </span></p>
<p style="top:516.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">we found that only EGCG,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">37,38</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> vitamin E,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">44,53</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> reserva-</span></p>
<p style="top:528.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">trol,</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">33,35</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and ALA</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">66,69,70</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> promoted remyelination and/</span></p>
<p style="top:540.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">or protected neurons from inflammatory-mediated </span></p>
<p style="top:552.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">damage (in animal models). Resveratrol consistently </span></p>
<p style="top:564.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">provided neuroprotection in EAE, though this was </span></p>
<p style="top:576.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">independent of any anti-inflammatory benefits.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">33,35</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:588.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Clinical studies included in this review provided </span></p>
<p style="top:600.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">short term outcomes (predominantly 12 weeks post-</span></p>
<p style="top:612.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treatment) with no effects of OTC anti-oxidants on </span></p>
<p style="top:624.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the disease course (EDSS score). If it is purported that </span></p>
<p style="top:636.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">anti-oxidants convey their benefits by interfering with </span></p>
<p style="top:648.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the inflammatory cascade and preventing axonal </span></p>
<p style="top:660.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">damage then longer term outcomes, such as lesion </span></p>
<p style="top:672.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">accumulation, number of relapses, or recovery post-</span></p>
<p style="top:684.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">relapse, should be included in future studies. In other </span></p>
<p style="top:696.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neurodegenerative diseases, for example, vitamin E </span></p>
<p style="top:708.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for six months to four years significantly slowed </span></p>
<p style="top:720.0pt;left:268.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">functional decline among people with Alzheimer&#x2019;s </span></p>


<p style="top:34.3pt;left:25.5pt;line-height:10.5pt"><i><span style="font-family:Times New Roman,serif;font-size:10.5pt">Multiple Sclerosis Journal</span></i><span style="font-family:Times New Roman,serif;font-size:10.5pt"> 21(12)</span></p>
<p style="top:755.1pt;left:25.5pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">1492 </span></p>
<p style="top:755.1pt;left:492.1pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">http://msj.sagepub.com</span></p>
<p style="top:72.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">disease.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">81</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> There are also opportunities to develop new </span></p>
<p style="top:84.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">degenerative models that exhibit ROS-related nerv-</span></p>
<p style="top:96.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ous system injury to test potentially neuroprotective </span></p>
<p style="top:108.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">compounds.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">82</span></sup></p>
<p style="top:144.0pt;left:113.4pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Translating preclinical results to clinical trials</span></i></p>
<p style="top:156.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Patients with MS likely ingest OTC anti-oxidants, </span></p>
<p style="top:168.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and all the clinical studies we reviewed used oral </span></p>
<p style="top:180.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">administration. However, in most animal studies, </span></p>
<p style="top:192.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">anti-oxidant compounds were administered by either </span></p>
<p style="top:204.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">subcutaneous or i.p. injection, making it challenging </span></p>
<p style="top:216.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to translate to the clinical setting. At least with ALA </span></p>
<p style="top:228.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treatment of EAE, injection was superior to oral </span></p>
<p style="top:240.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">administration.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">26,29,70</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> For other compounds, direct </span></p>
<p style="top:252.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">administration into the blood may not always improve </span></p>
<p style="top:264.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">bioavailability; passage through the gastrointestinal </span></p>
<p style="top:276.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tract could be needed to see any beneficial effects.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">83</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:288.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Several studies showed that absorption of the product </span></p>
<p style="top:300.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">varied extensively between individuals and by prod-</span></p>
<p style="top:312.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">uct formulation, such as ALA</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">62,72</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> and </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">84</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:324.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Still, bioavailability in the circulation does not neces-</span></p>
<p style="top:336.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sarily mean that compounds can affect the CNS. For </span></p>
<p style="top:348.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">many of the compounds studied, it was unclear </span></p>
<p style="top:360.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">whether they crossed the blood-brain barrier to the </span></p>
<p style="top:372.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">site of their potential action. More studies examining </span></p>
<p style="top:384.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pharmacokinetics particularly blood-brain barrier </span></p>
<p style="top:396.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">penetration, are required.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">84&#x2013;86</span></sup></p>
<p style="top:420.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Another key concern for the safety of people with MS </span></p>
<p style="top:432.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">is toleration of anti-oxidant diets and supplements. </span></p>
<p style="top:444.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Our findings suggest that in both humans and ani-</span></p>
<p style="top:456.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mals, anti-oxidant products were reasonably toler-</span></p>
<p style="top:468.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ated. Studies did not report animal mortality related to </span></p>
<p style="top:480.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the intervention; and side effects experienced in clini-</span></p>
<p style="top:492.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cal trials were mild, such as gastrointestinal upset (</span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">G. </span></i></p>
<p style="top:504.0pt;left:113.4pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">biloba</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> 240 mg/day, ALA 1200 mg/day).</span></p>
<p style="top:540.0pt;left:113.4pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Improving the quality of anti-oxidant research  </span></i></p>
<p style="top:552.0pt;left:113.4pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">in MS</span></i></p>
<p style="top:564.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">We assessed risk-of-bias using validated tools for </span></p>
<p style="top:576.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">both the clinical studies and studies involving animal </span></p>
<p style="top:588.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">models. We identified four areas for improvement for </span></p>
<p style="top:600.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">future research. In addition to mode of compound </span></p>
<p style="top:612.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">administration and duration of assessment mentioned </span></p>
<p style="top:624.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">above, we noted that about half of the protocols did </span></p>
<p style="top:636.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">not include blinding of assessors, and there was exten-</span></p>
<p style="top:648.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sive use of subjective rating scales of behavioral out-</span></p>
<p style="top:660.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">comes. Since the behavioral and clinical measures </span></p>
<p style="top:672.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">require subjectivity by the assessor, this is a concern. </span></p>
<p style="top:684.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">As discussed by researchers in other fields, strength-</span></p>
<p style="top:696.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ening preclinical research methodology facilitates </span></p>
<p style="top:708.0pt;left:113.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">knowledge translation.</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">18,19</span></sup></p>
<p style="top:72.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In summary, our review provides a preliminary frame-</span></p>
<p style="top:84.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">work for the benefits of anti-oxidant diets in alleviat-</span></p>
<p style="top:96.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ing the progression of MS and describes key areas of </span></p>
<p style="top:108.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improvement for future animal and clinical studies. </span></p>
<p style="top:120.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Although some preclinical results are promising, at </span></p>
<p style="top:132.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">this time, the evidence suggests that OTC anti-oxi-</span></p>
<p style="top:144.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">dants do not alter the disease in people with MS.</span></p>
<p style="top:168.0pt;left:339.1pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Conflict of interest</span></b></p>
<p style="top:180.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">None declared.</span></p>
<p style="top:204.0pt;left:339.1pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">Funding</span></b></p>
<p style="top:216.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">This study was supported by the endMS Research </span></p>
<p style="top:228.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Training Network, Scholar Program for Researchers in </span></p>
<p style="top:240.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Training (SPRINT) and the MS Society of Canada. </span></p>
<p style="top:252.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">JRP is supported by the Donna Joan Oxford Postdoctoral </span></p>
<p style="top:264.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Fellowship Award from the Multiple Sclerosis Society </span></p>
<p style="top:276.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of Canada and by postdoctoral fellowships awards </span></p>
<p style="top:288.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">from the Canadian Institutes of Health Research </span></p>
<p style="top:300.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(CIHR) and T. Chen Fong. CJ is supported by a CIHR </span></p>
<p style="top:312.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Vanier Graduate Canada Scholarship and by fellowship </span></p>
<p style="top:324.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">awards from the Multiple Sclerosis Society of Canada </span></p>
<p style="top:336.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and the CIHR Neuroinflammation Training Program. </span></p>
<p style="top:348.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">CB is supported by a Multiple Sclerosis Society of </span></p>
<p style="top:360.0pt;left:339.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Canada graduate fellowship.</span></p>
<p style="top:408.0pt;left:339.1pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#005337">References</span></b></p>
<p style="top:419.8pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 1. Bjartmar C and Trapp BD. Axonal degeneration and </span></p>
<p style="top:430.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">progressive neurologic disability in multiple sclerosis. </span></p>
<p style="top:441.8pt;left:357.1pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neurotox Res</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2003; 5: 157&#x2013;164.</span></p>
<p style="top:458.8pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal </span></p>
<p style="top:469.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">antibody treatment exposes three mechanisms </span></p>
<p style="top:480.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">underlying the clinical course of multiple sclerosis. </span></p>
<p style="top:491.8pt;left:357.1pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Ann Neurol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 1999; 46: 296&#x2013;304.</span></p>
<p style="top:508.8pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 3. Metz I, Lucchinetti CF, Openshaw H, et al. </span></p>
<p style="top:519.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Autologous haematopoietic stem cell transplantation </span></p>
<p style="top:530.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">fails to stop demyelination and neurodegeneration in </span></p>
<p style="top:541.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">multiple sclerosis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Brain</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2007; 130: 1254&#x2013;1262.</span></p>
<p style="top:558.8pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 4. Scalfari A, Neuhaus A, Degenhardt A, et al. The </span></p>
<p style="top:569.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">natural history of multiple sclerosis: A geographically </span></p>
<p style="top:580.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">based study 10: Relapses and long-term disability. </span></p>
<p style="top:591.8pt;left:357.1pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Brain</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2010; 133: 1914&#x2013;1929.</span></p>
<p style="top:608.8pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 5. Trapp BD and Stys PK. Virtual hypoxia and chronic </span></p>
<p style="top:619.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">necrosis of demyelinated axons in multiple sclerosis. </span></p>
<p style="top:630.8pt;left:357.1pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Lancet Neurol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2009; 8: 280&#x2013;291.</span></p>
<p style="top:647.8pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 6. Geurts JJ, Stys PK, Minagar A, et al. Gray matter </span></p>
<p style="top:658.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">pathology in (chronic) MS: Modern views on an early </span></p>
<p style="top:669.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">observation. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Neurol Sci</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2009; 282: 12&#x2013;20.</span></p>
<p style="top:686.8pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 7. Rudick RA and Trapp BD. Gray-matter injury in </span></p>
<p style="top:697.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">multiple sclerosis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">N Engl J Med</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2009; 361: 1505&#x2013;</span></p>
<p style="top:708.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">1506.</span></p>


<p style="top:34.3pt;left:451.1pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">JR Plemel, CA Juzwik </span><i><span style="font-family:Times New Roman,serif;font-size:10.5pt">et al.</span></i></p>
<p style="top:755.1pt;left:42.5pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">http://msj.sagepub.com </span></p>
<p style="top:755.1pt;left:556.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">1493</span></p>
<p style="top:71.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 8. Franklin RJ, ffrench-Constant C, Edgar JM, et al. </span></p>
<p style="top:82.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neuroprotection and repair in multiple sclerosis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Nat </span></i></p>
<p style="top:93.8pt;left:60.5pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Rev Neurol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2012; 8: 624&#x2013;634.</span></p>
<p style="top:110.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 9. Smith KJ, Kapoor R and Felts PA. Demyelination: </span></p>
<p style="top:121.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">The role of reactive oxygen and nitrogen species. </span></p>
<p style="top:132.8pt;left:60.5pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Brain Pathol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 1999; 9: 69&#x2013;92.</span></p>
<p style="top:149.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 10. Haider L, Fischer MT, Frischer JM, et al. Oxidative </span></p>
<p style="top:160.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">damage in multiple sclerosis lesions. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Brain</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2011; </span></p>
<p style="top:171.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">134: 1914&#x2013;1924.</span></p>
<p style="top:188.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 11. Cross AH, Manning PT, Keeling RM, et al. </span></p>
<p style="top:199.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Peroxynitrite formation within the central nervous </span></p>
<p style="top:210.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">system in active multiple sclerosis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Neuroimmunol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:221.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">1998; 88: 45&#x2013;56.</span></p>
<p style="top:237.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 12. Liu JS, Zhao ML, Brosnan CF, et al. Expression of </span></p>
<p style="top:248.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">inducible nitric oxide synthase and nitrotyrosine in </span></p>
<p style="top:259.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">multiple sclerosis lesions. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Am J Pathol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2001; 158: </span></p>
<p style="top:270.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2057&#x2013;2066.</span></p>
<p style="top:286.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 13. Fischer MT, Sharma R, Lim JL, et al. NADPH </span></p>
<p style="top:297.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">oxidase expression in active multiple sclerosis </span></p>
<p style="top:308.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">lesions in relation to oxidative tissue damage and </span></p>
<p style="top:319.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">mitochondrial injury. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Brain</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2012; 135: 886&#x2013;899.</span></p>
<p style="top:336.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 14. Nikic I, Merkler D, Sorbara C, et al. A reversible </span></p>
<p style="top:347.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">form of axon damage in experimental autoimmune </span></p>
<p style="top:358.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">encephalomyelitis and multiple sclerosis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Nat Med</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:369.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2011; 17: 495&#x2013;499.</span></p>
<p style="top:386.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 15. Masullo L, Papas MA, Cotugna N, et al. </span></p>
<p style="top:397.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Complementary and alternative medicine use and </span></p>
<p style="top:408.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">nutrient intake among individuals with multiple </span></p>
<p style="top:419.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">sclerosis in the United States. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Commun Health</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:430.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2015; 40: 153&#x2013;160.</span></p>
<p style="top:447.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 16. Liberati A, Altman DG, Tetzlaff J, et al. The </span></p>
<p style="top:458.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">PRISMA statement for reporting systematic reviews </span></p>
<p style="top:469.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">and meta-analyses of studies that evaluate health care </span></p>
<p style="top:480.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">interventions: Explanation and elaboration. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Clin </span></i></p>
<p style="top:491.8pt;left:60.5pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Epidemiol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2009; 62: e1&#x2013;34.</span></p>
<p style="top:508.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 17. DerSimonian R and Laird N. Meta-analysis in clinical </span></p>
<p style="top:519.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">trials. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Control Clin Trials</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 1986; 7: 177&#x2013;188.</span></p>
<p style="top:536.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 18. Vesterinen HM, Egan K, Deister A, et al. Systematic </span></p>
<p style="top:547.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">survey of the design, statistical analysis, and </span></p>
<p style="top:558.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">reporting of studies published in the 2008 volume </span></p>
<p style="top:569.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of the </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Journal of Cerebral Blood Flow and </span></i></p>
<p style="top:580.8pt;left:60.5pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Metabolism</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt">. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Cereb Blood Flow Metab</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2011; 31: </span></p>
<p style="top:591.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">1064&#x2013;1072.</span></p>
<p style="top:608.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 19. Sena E, van der Worp HB, Howells D, et al. How can </span></p>
<p style="top:619.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">we improve the pre-clinical development of drugs for </span></p>
<p style="top:630.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">stroke? </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Trends Neurosci</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2007; 30: 433&#x2013;439.</span></p>
<p style="top:647.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 20. Liu B, Shen Y, Xiao K, et al. Serum uric acid levels </span></p>
<p style="top:658.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">in patients with multiple sclerosis: A meta-analysis. </span></p>
<p style="top:669.8pt;left:60.5pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neurol Res</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2012; 34: 163&#x2013;171.</span></p>
<p style="top:685.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 21. Spitsin S and Koprowski H. Role of uric acid in </span></p>
<p style="top:696.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">multiple sclerosis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Curr Top Microbiol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2008; 318: </span></p>
<p style="top:707.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">325&#x2013;342.</span></p>
<p style="top:71.8pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 22. Koch M and De Keyser J. Uric acid in multiple </span></p>
<p style="top:82.8pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">sclerosis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neurol Res</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2006; 28: 316&#x2013;319.</span></p>
<p style="top:99.8pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 23. Farinotti M, Vacchi L, Simi S, et al. Dietary </span></p>
<p style="top:110.8pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">interventions for multiple sclerosis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Cochrane </span></i></p>
<p style="top:121.8pt;left:286.2pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Database Syst Rev</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2012; 12: CD004192.</span></p>
<p style="top:138.8pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 24. Scalbert A, Johnson IT and Saltmarsh M. </span></p>
<p style="top:149.8pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Polyphenols: Antioxidants and beyond. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Am J Clin </span></i></p>
<p style="top:160.8pt;left:286.2pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Nutr</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2005; 81: 215S&#x2013;217S.</span></p>
<p style="top:177.8pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 25. Tangney CC and Rasmussen HE. Polyphenols, </span></p>
<p style="top:188.8pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">inflammation, and cardiovascular disease. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Curr </span></i></p>
<p style="top:199.8pt;left:286.2pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Atheroscler Rep</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2013; 15: 324.</span></p>
<p style="top:216.8pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 26. Hendriks JJ, Alblas J, van der Pol SM, et al. </span></p>
<p style="top:227.8pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Flavonoids influence monocytic GTPase activity and </span></p>
<p style="top:238.8pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">are protective in experimental allergic encephalitis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J </span></i></p>
<p style="top:249.8pt;left:286.2pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Exp Med</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2004; 200: 1667&#x2013;1672.</span></p>
<p style="top:266.8pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 27. Muthian G and Bright JJ. Quercetin, a flavonoid </span></p>
<p style="top:277.8pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">phytoestrogen, ameliorates experimental allergic </span></p>
<p style="top:288.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">encephalomyelitis by blocking IL-12 signaling </span></p>
<p style="top:299.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">through JAK-STAT pathway in T lymphocyte. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Clin </span></i></p>
<p style="top:310.7pt;left:286.2pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Immunol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2004; 24: 542&#x2013;552.</span></p>
<p style="top:327.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 28. Sternberg Z, Chadha K, Lieberman A, et al. Quercetin </span></p>
<p style="top:338.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">and interferon-beta modulate immune response(s) </span></p>
<p style="top:349.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">in peripheral blood mononuclear cells isolated from </span></p>
<p style="top:360.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">multiple sclerosis patients. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Neuroimmunol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2008; </span></p>
<p style="top:371.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">205: 142&#x2013;147.</span></p>
<p style="top:388.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 29. Verbeek R, van Tol EA and van Noort JM. Oral </span></p>
<p style="top:399.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">flavonoids delay recovery from experimental </span></p>
<p style="top:410.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">autoimmune encephalomyelitis in SJL mice. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Biochem </span></i></p>
<p style="top:421.7pt;left:286.2pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Pharmacol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2005; 70: 220&#x2013;228.</span></p>
<p style="top:438.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 30. Sternberg Z, Chadha K, Lieberman A, et al. </span></p>
<p style="top:449.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Immunomodulatory responses of peripheral blood </span></p>
<p style="top:460.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">mononuclear cells from multiple sclerosis patients </span></p>
<p style="top:471.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">upon in vitro incubation with the flavonoid luteolin: </span></p>
<p style="top:482.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Additive effects of IFN-beta. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Neuroinflammation</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:493.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2009; 6: 28.</span></p>
<p style="top:512.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 31. Natarajan C and Bright JJ. Curcumin inhibits </span></p>
<p style="top:523.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">experimental allergic encephalomyelitis by blocking </span></p>
<p style="top:534.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">IL-12 signaling through Janus kinase-STAT pathway </span></p>
<p style="top:545.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">in T lymphocytes. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Immunol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2002; 168: 6506&#x2013;6513.</span></p>
<p style="top:563.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 32. Xie L, Li XK, Funeshima-Fuji N, et al. Amelioration </span></p>
<p style="top:574.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of experimental autoimmune encephalomyelitis </span></p>
<p style="top:585.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">by curcumin treatment through inhibition of IL-17 </span></p>
<p style="top:596.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">production. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Int Immunopharmacol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2009; 9: 575&#x2013;581.</span></p>
<p style="top:613.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 33. Fonseca-Kelly Z, Nassrallah M, Uribe J, et al. </span></p>
<p style="top:624.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Resveratrol neuroprotection in a chronic mouse </span></p>
<p style="top:635.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">model of multiple sclerosis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Front Neurol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2012; 3: 84.</span></p>
<p style="top:652.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 34. Imler TJ, Jr. and Petro TM. Decreased severity of </span></p>
<p style="top:663.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">experimental autoimmune encephalomyelitis during </span></p>
<p style="top:674.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">resveratrol administration is associated with increased </span></p>
<p style="top:685.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">IL-17+IL-10+ T cells, CD4(-) IFN-gamma+ cells, </span></p>
<p style="top:696.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">and decreased macrophage IL-6 expression. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Int </span></i></p>
<p style="top:707.7pt;left:286.2pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Immunopharmacol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2009; 9: 134&#x2013;143.</span></p>


<p style="top:34.3pt;left:25.5pt;line-height:10.5pt"><i><span style="font-family:Times New Roman,serif;font-size:10.5pt">Multiple Sclerosis Journal</span></i><span style="font-family:Times New Roman,serif;font-size:10.5pt"> 21(12)</span></p>
<p style="top:755.1pt;left:25.5pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">1494 </span></p>
<p style="top:755.1pt;left:492.1pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">http://msj.sagepub.com</span></p>
<p style="top:71.8pt;left:113.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 35. Shindler KS, Ventura E, Dutt M, et al. Oral </span></p>
<p style="top:82.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">resveratrol reduces neuronal damage in a model of </span></p>
<p style="top:93.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">multiple sclerosis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Neuroophthalmol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2010; 30: </span></p>
<p style="top:104.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">328&#x2013;339.</span></p>
<p style="top:121.8pt;left:113.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 36. Singh NP, Hegde VL, Hofseth LJ, et al. Resveratrol </span></p>
<p style="top:132.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">(trans-3,5,4&#x2019;-trihydroxystilbene) ameliorates </span></p>
<p style="top:143.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">experimental allergic encephalomyelitis, primarily via </span></p>
<p style="top:154.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">induction of apoptosis in T cells involving activation </span></p>
<p style="top:165.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of aryl hydrocarbon receptor and estrogen receptor. </span></p>
<p style="top:176.8pt;left:131.4pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Mol Pharmacol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2007; 72: 1508&#x2013;1521.</span></p>
<p style="top:193.8pt;left:113.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 37. Aktas O, Prozorovski T, Smorodchenko A, et al. </span></p>
<p style="top:204.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Green tea epigallocatechin-3-gallate mediates </span></p>
<p style="top:215.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">T cellular NF-kappa B inhibition and exerts </span></p>
<p style="top:226.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">neuroprotection in autoimmune encephalomyelitis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J </span></i></p>
<p style="top:237.8pt;left:131.4pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Immunol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2004; 173: 5794&#x2013;5800.</span></p>
<p style="top:254.8pt;left:113.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 38. Herges K, Millward JM, Hentschel N, et al. </span></p>
<p style="top:265.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neuroprotective effect of combination therapy of </span></p>
<p style="top:276.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">glatiramer acetate and epigallocatechin-3-gallate in </span></p>
<p style="top:287.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">neuroinflammation. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">PLoS One</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2011; 6: e25456.</span></p>
<p style="top:304.8pt;left:113.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 39. Sun Q, Zheng Y, Zhang X, et al. Novel </span></p>
<p style="top:315.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">immunoregulatory properties of EGCG on reducing </span></p>
<p style="top:326.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">inflammation in EAE. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Front Biosci (Landmark Ed)</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:337.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2013; 18: 332&#x2013;342.</span></p>
<p style="top:354.8pt;left:113.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 40. Wang J, Ren Z, Xu Y, et al. Epigallocatechin-</span></p>
<p style="top:365.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3-gallate ameliorates experimental autoimmune </span></p>
<p style="top:376.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">encephalomyelitis by altering balance among CD4+ </span></p>
<p style="top:387.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">T-cell subsets. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Am J Pathol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2012; 180: 221&#x2013;234.</span></p>
<p style="top:404.8pt;left:113.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 41. Barry J, Fritz M, Brender JR, et al. Determining the </span></p>
<p style="top:415.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">effects of lipophilic drugs on membrane structure </span></p>
<p style="top:426.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">by solid-state NMR spectroscopy: The case of the </span></p>
<p style="top:437.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">antioxidant curcumin. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Am Chem Soc</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2009; 131: </span></p>
<p style="top:448.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">4490&#x2013;4498.</span></p>
<p style="top:465.8pt;left:113.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 42. Wang KC, Tsai CP, Lee CL, et al. alpha-Lipoic </span></p>
<p style="top:476.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">acid enhances endogenous peroxisome-proliferator-</span></p>
<p style="top:487.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">activated receptor-gamma to ameliorate experimental </span></p>
<p style="top:498.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">autoimmune encephalomyelitis in mice. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Clin Sci </span></i></p>
<p style="top:509.8pt;left:131.4pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">(Lond)</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2013; 125: 329&#x2013;340.</span></p>
<p style="top:526.8pt;left:113.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 43. Furst R and Zundorf I. Plant-derived anti-</span></p>
<p style="top:537.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">inflammatory compounds: Hopes and </span></p>
<p style="top:548.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">disappointments regarding the translation of </span></p>
<p style="top:559.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">preclinical knowledge into clinical progress. </span></p>
<p style="top:570.8pt;left:131.4pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Mediators Inflamm</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2014; 2014: 146832.</span></p>
<p style="top:587.8pt;left:113.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 44. Goudarzvand M, Javan M, Mirnajafi-Zadeh J, et al. </span></p>
<p style="top:598.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Vitamins E and D3 attenuate demyelination and </span></p>
<p style="top:609.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">potentiate remyelination processes of hippocampal </span></p>
<p style="top:620.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">formation of rats following local injection of ethidium </span></p>
<p style="top:631.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">bromide. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Cell Mol Neurobiol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2010; 30: 289&#x2013;299.</span></p>
<p style="top:649.8pt;left:113.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 45. Jafarirad S, Siassi F, Harirchian MH, et al. The </span></p>
<p style="top:660.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">effect of vitamin A supplementation on biochemical </span></p>
<p style="top:671.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">parameters in multiple sclerosis patients. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Iran Red </span></i></p>
<p style="top:682.8pt;left:131.4pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Crescent Med J</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2013; 15: 194&#x2013;198.</span></p>
<p style="top:699.8pt;left:113.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 46. Jafarirad S, Siassi F, Harirchian MH, et al. The </span></p>
<p style="top:710.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">effect of vitamin A supplementation on stimulated </span></p>
<p style="top:721.8pt;left:131.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">T-cell proliferation with myelin oligodendrocyte </span></p>
<p style="top:71.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">glycoprotein in patients with multiple sclerosis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J </span></i></p>
<p style="top:82.8pt;left:357.1pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neurosci Rural Pract</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2012; 3: 294&#x2013;298.</span></p>
<p style="top:99.8pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 47. Mai J, Sorensen PS and Hansen JC. High dose </span></p>
<p style="top:110.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">antioxidant supplementation to MS patients. Effects on </span></p>
<p style="top:121.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">glutathione peroxidase, clinical safety, and absorption </span></p>
<p style="top:132.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of selenium. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Biol Trace Elem Res</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 1990; 24: 109&#x2013;117.</span></p>
<p style="top:149.8pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 48. Nordvik I, Myhr KM, Nyland H, et al. Effect of </span></p>
<p style="top:160.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">dietary advice and n-3 supplementation in newly </span></p>
<p style="top:171.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">diagnosed MS patients. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Acta Neurol Scand</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2000; 102: </span></p>
<p style="top:182.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">143&#x2013;149.</span></p>
<p style="top:199.7pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 49. Jensen GE and Clausen J. Glutathione peroxidase </span></p>
<p style="top:210.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">activity, associated enzymes and substrates in blood </span></p>
<p style="top:221.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">cells from patients with multiple sclerosis &#x2013; effects of </span></p>
<p style="top:232.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">antioxidant supplementation. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Acta Pharmacol Toxicol </span></i></p>
<p style="top:243.7pt;left:357.1pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">(Copenh)</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 1986; 59 (Suppl 7): 450&#x2013;453.</span></p>
<p style="top:260.7pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 50. Pantzaris MC, Loukaides GN, Ntzani EE, et al. </span></p>
<p style="top:271.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">A novel oral nutraceutical formula of omega-3 </span></p>
<p style="top:282.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">and omega-6 fatty acids with vitamins (PLP10) in </span></p>
<p style="top:293.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">relapsing remitting multiple sclerosis: A randomised, </span></p>
<p style="top:304.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">double-blind, placebo-controlled proof-of-concept </span></p>
<p style="top:315.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">clinical trial. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">BMJ Open</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2013; 3: e002170.  </span></p>
<p style="top:326.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">DOI: 10.1136/bmjopen-2012-002170.</span></p>
<p style="top:343.7pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 51. Ramsaransing GS, Mellema SA and De Keyser J. </span></p>
<p style="top:354.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Dietary patterns in clinical subtypes of multiple </span></p>
<p style="top:365.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">sclerosis: An exploratory study. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Nutr J</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2009; 8: 36.</span></p>
<p style="top:382.7pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 52. Shinto L, Calabrese C, Morris C, et al. A randomized </span></p>
<p style="top:393.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">pilot study of naturopathic medicine in multiple </span></p>
<p style="top:404.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">sclerosis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Altern Complement Med</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2008; 14: 489&#x2013;496.</span></p>
<p style="top:421.7pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 53. Spanevello R, Mazzanti CM, Schmatz R, et al. </span></p>
<p style="top:432.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Effect of vitamin E on ectonucleotidase activities </span></p>
<p style="top:443.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">in synaptosomes and platelets and parameters of </span></p>
<p style="top:454.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">oxidative stress in rats experimentally demyelinated. </span></p>
<p style="top:465.7pt;left:357.1pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Brain Res Bull</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2009; 80: 45&#x2013;51.</span></p>
<p style="top:482.7pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 54. Spitsin SV, Scott GS, Mikheeva T, et al. Comparison </span></p>
<p style="top:493.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of uric acid and ascorbic acid in protection against </span></p>
<p style="top:504.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EAE. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Free Radic Biol Med</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2002; 33: 1363&#x2013;1371.</span></p>
<p style="top:521.7pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 55. Vladutiu A and Cringulescu N. Suppression of </span></p>
<p style="top:532.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">experimental allergic encephalomyelitis by vitamin </span></p>
<p style="top:543.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">A. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Experientia</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 1968; 24: 718&#x2013;719.</span></p>
<p style="top:560.7pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 56. Zhang SM, Hernan MA, Olek MJ, et al. Intakes of </span></p>
<p style="top:571.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">carotenoids, vitamin C, and vitamin E and MS risk </span></p>
<p style="top:582.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">among two large cohorts of women. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neurology</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2001; </span></p>
<p style="top:593.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">57: 75&#x2013;80.</span></p>
<p style="top:610.7pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 57. Brigelius-Floh&#xe9; R and Traber MG. Vitamin E: Function </span></p>
<p style="top:621.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">and metabolism. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">FASEB J</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 1999; 13: 1145&#x2013;1155.</span></p>
<p style="top:638.7pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 58. Boscoboinik D, Szewczyk A and Azzi A. Alpha-</span></p>
<p style="top:649.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">tocopherol (vitamin E) regulates vascular smooth </span></p>
<p style="top:660.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">muscle cell proliferation and protein kinase C activity. </span></p>
<p style="top:671.7pt;left:357.1pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Arch Biochem Biophys</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 1991; 286: 264&#x2013;269.</span></p>
<p style="top:688.7pt;left:339.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 59. Chan AC, Wagner M, Kennedy C, et al. Vitamin </span></p>
<p style="top:699.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">E up-regulates arachidonic acid release and </span></p>
<p style="top:710.7pt;left:357.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">phospholipase A2 in megakaryocytes. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Mol Cell </span></i></p>
<p style="top:721.7pt;left:357.1pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Biochem</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 1998; 189: 153&#x2013;159.</span></p>


<p style="top:34.3pt;left:451.1pt;line-height:10.5pt"><span style="font-family:Times New Roman,serif;font-size:10.5pt">JR Plemel, CA Juzwik </span><i><span style="font-family:Times New Roman,serif;font-size:10.5pt">et al.</span></i></p>
<p style="top:755.1pt;left:42.5pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">http://msj.sagepub.com </span></p>
<p style="top:755.1pt;left:556.8pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">1495</span></p>
<p style="top:71.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 60. Nebbioso M, Pranno F and Pescosolido N. Lipoic acid </span></p>
<p style="top:82.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">in animal models and clinical use in diabetic retinopathy. </span></p>
<p style="top:93.8pt;left:60.5pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Expert Opin Pharmacother</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2013; 14: 1829&#x2013;1838.</span></p>
<p style="top:110.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 61. Rochette L, Ghibu S, Richard C, et al. Direct and </span></p>
<p style="top:121.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">indirect antioxidant properties of alpha-lipoic acid </span></p>
<p style="top:132.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">and therapeutic potential. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Mol Nutr Food Res</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2013; </span></p>
<p style="top:143.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">57: 114&#x2013;125.</span></p>
<p style="top:161.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 62. Yadav V, Marracci GH, Munar MY, et al. </span></p>
<p style="top:172.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Pharmacokinetic study of lipoic acid in multiple </span></p>
<p style="top:183.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">sclerosis: Comparing mice and human pharmacokinetic </span></p>
<p style="top:194.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">parameters. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Mult Scler</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2010; 16: 387&#x2013;397.</span></p>
<p style="top:212.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 63. Salinthone S, Yadav V, Schillace RV, et al. Lipoic </span></p>
<p style="top:223.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">acid attenuates inflammation via cAMP and protein </span></p>
<p style="top:234.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">kinase A signaling. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">PLoS One</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2010; 5(9): e13058. </span></p>
<p style="top:245.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">DOI: 10.1371/journal.pone.0013058.</span></p>
<p style="top:262.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 64. Khalili M, Azimi A, Izadi V, et al. Does lipoic acid </span></p>
<p style="top:273.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">consumption affect the cytokine profile in multiple </span></p>
<p style="top:284.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">sclerosis patients: A double-blind, placebo-controlled, </span></p>
<p style="top:295.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">randomized clinical trial. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neuroimmunomodulation</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:306.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2014; 21(6): 291&#x2013;6. DOI: 10.1159/000356145.</span></p>
<p style="top:323.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 65. Khalili M, Eghtesadi S, Mirshafiey A, et al. Effect of </span></p>
<p style="top:334.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">lipoic acid consumption on oxidative stress among </span></p>
<p style="top:345.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">multiple sclerosis patients: A randomized controlled </span></p>
<p style="top:356.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">clinical trial. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Nutr Neurosci</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2014; 17: 16&#x2013;20.</span></p>
<p style="top:374.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 66. Chaudhary P, Marracci G, Yu X, et al. Lipoic acid </span></p>
<p style="top:385.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">decreases inflammation and confers neuroprotection </span></p>
<p style="top:396.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">in experimental autoimmune optic neuritis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J </span></i></p>
<p style="top:407.8pt;left:60.5pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neuroimmunol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2011; 233: 90&#x2013;96.</span></p>
<p style="top:425.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 67. Chaudhary P, Marracci GH and Bourdette DN. Lipoic </span></p>
<p style="top:436.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">acid inhibits expression of ICAM-1 and VCAM-1 </span></p>
<p style="top:447.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">by CNS endothelial cells and T cell migration </span></p>
<p style="top:458.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">into the spinal cord in experimental autoimmune </span></p>
<p style="top:469.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">encephalomyelitis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Neuroimmunol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2006; 175: 87&#x2013;96.</span></p>
<p style="top:487.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 68. Jones RE, Moes N, Zwickey H, et al. Treatment of </span></p>
<p style="top:498.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">experimental autoimmune encephalomyelitis with </span></p>
<p style="top:509.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">alpha lipoic acid and associative conditioning. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Brain </span></i></p>
<p style="top:520.8pt;left:60.5pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Behav Immun</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2008; 22: 538&#x2013;543.</span></p>
<p style="top:538.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 69. Marracci GH, Jones RE, McKeon GP, et al. Alpha </span></p>
<p style="top:549.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">lipoic acid inhibits T cell migration into the spinal </span></p>
<p style="top:560.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">cord and suppresses and treats experimental </span></p>
<p style="top:571.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">autoimmune encephalomyelitis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Neuroimmunol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:582.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2002; 131: 104&#x2013;114.</span></p>
<p style="top:599.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 70. Morini M, Roccatagliata L, Dell&#x2019;Eva R, et al. Alpha-</span></p>
<p style="top:610.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">lipoic acid is effective in prevention and treatment </span></p>
<p style="top:621.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of experimental autoimmune encephalomyelitis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J </span></i></p>
<p style="top:632.8pt;left:60.5pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neuroimmunol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2004; 148: 146&#x2013;153.</span></p>
<p style="top:649.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 71. Schreibelt G, Musters RJ, Reijerkerk A, et al. Lipoic </span></p>
<p style="top:660.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">acid affects cellular migration into the central nervous </span></p>
<p style="top:671.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">system and stabilizes blood-brain barrier integrity. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J </span></i></p>
<p style="top:682.8pt;left:60.5pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Immunol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2006; 177: 2630&#x2013;2637.</span></p>
<p style="top:699.8pt;left:42.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 72. Yadav V, Marracci G, Lovera J, et al. Lipoic acid in </span></p>
<p style="top:710.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">multiple sclerosis: A pilot study. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Mult Scler</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2005; 11: </span></p>
<p style="top:721.8pt;left:60.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">159&#x2013;165.</span></p>
<p style="top:71.8pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 73. van Beek TA. Chemical analysis of </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Ginkgo biloba</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:82.8pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">leaves and extracts. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Chromatogr A</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2002; 967: 21&#x2013;55.</span></p>
<p style="top:99.8pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 74. Johnson SK, Diamond BJ, Rausch S, et al. The effect </span></p>
<p style="top:110.8pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Ginkgo biloba</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> on functional measures in multiple </span></p>
<p style="top:121.8pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">sclerosis: A pilot randomized controlled trial. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Explore </span></i></p>
<p style="top:132.8pt;left:286.2pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">(NY)</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2006; 2: 19&#x2013;24.</span></p>
<p style="top:149.8pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 75. Lovera JF, Kim E, Heriza E, et al. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Ginkgo biloba</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> does </span></p>
<p style="top:160.8pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">not improve cognitive function in MS: A randomized </span></p>
<p style="top:171.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">placebo-controlled trial. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neurology</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2012; 79: </span></p>
<p style="top:182.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">1278&#x2013;1284.</span></p>
<p style="top:199.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 76. Lovera J, Bagert B, Smoot K, et al. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Ginkgo biloba</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:210.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">for the improvement of cognitive performance in </span></p>
<p style="top:221.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">multiple sclerosis: A randomized, placebo-controlled </span></p>
<p style="top:232.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">trial. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Mult Scler</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2007; 13: 376&#x2013;385.</span></p>
<p style="top:249.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 77. Noroozian M M-RS, Tasviechi AK, Sahraian MA, </span></p>
<p style="top:260.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">et al. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Gingko biloba</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> for improvement of memory and </span></p>
<p style="top:271.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">quality of life in multiple sclerosis: An open trial. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J </span></i></p>
<p style="top:282.7pt;left:286.2pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Med Plants</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2011; 10: 33&#x2013;42.</span></p>
<p style="top:299.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 78. Diamond BJ, Johnson SK, Kaufman M, et al. A </span></p>
<p style="top:310.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">randomized controlled pilot trial: The effects of EGb </span></p>
<p style="top:321.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">761 on information processing and executive function </span></p>
<p style="top:332.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">in multiple sclerosis. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Explore (NY)</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2013; 9: 106&#x2013;107.</span></p>
<p style="top:349.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 79. Hawker K, O&#x2019;Connor P, Freedman MS, et al. </span></p>
<p style="top:360.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Rituximab in patients with primary progressive </span></p>
<p style="top:371.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">multiple sclerosis: Results of a randomized double-</span></p>
<p style="top:382.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">blind placebo-controlled multicenter trial. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Ann Neurol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:393.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2009; 66: 460&#x2013;471.</span></p>
<p style="top:410.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 80. Lassmann H. Multiple sclerosis: Lessons from molecular </span></p>
<p style="top:421.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">neuropathology. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Exp Neurol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2013; 262(Part A): 2&#x2013;7.</span></p>
<p style="top:438.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 81. Dysken MW, Sano M, Asthana S, et al. Effect of </span></p>
<p style="top:449.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">vitamin E and memantine on functional decline in </span></p>
<p style="top:460.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Alzheimer disease: The TEAM-AD VA cooperative </span></p>
<p style="top:471.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">randomized trial. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">JAMA</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2014; 311: 33&#x2013;44.</span></p>
<p style="top:488.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 82. Schuh C, Wimmer I, Hametner S, et al. Oxidative </span></p>
<p style="top:499.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">tissue injury in multiple sclerosis is only partly </span></p>
<p style="top:510.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">reflected in experimental disease models. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Acta </span></i></p>
<p style="top:521.7pt;left:286.2pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neuropathol</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2014; 128: 247&#x2013;266.</span></p>
<p style="top:538.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 83. Ratnam DV, Ankola DD, Bhardwaj V, et al. Role </span></p>
<p style="top:549.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of antioxidants in prophylaxis and therapy: A </span></p>
<p style="top:560.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">pharmaceutical perspective. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Control Release</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2006; </span></p>
<p style="top:571.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">113: 189&#x2013;207.</span></p>
<p style="top:588.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 84. Ude C, Schubert-Zsilavecz M and Wurglics </span></p>
<p style="top:599.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">M. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Ginkgo biloba</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> extracts: A review of the </span></p>
<p style="top:610.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">pharmacokinetics of the active ingredients. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Clin </span></i></p>
<p style="top:621.7pt;left:286.2pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Pharmacokinet</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2013; 52: 727&#x2013;749.</span></p>
<p style="top:638.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 85. Chng HT, New LS, Neo AH, et al. Distribution study </span></p>
<p style="top:649.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of orally administered lipoic acid in rat brain tissues. </span></p>
<p style="top:660.7pt;left:286.2pt;line-height:9.0pt"><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">Brain Res</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2009; 1251: 80&#x2013;86.</span></p>
<p style="top:677.7pt;left:268.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 86. Lin LC, Wang MN, Tseng TY, et al. </span></p>
<p style="top:688.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Pharmacokinetics of (-)-epigallocatechin-3-gallate </span></p>
<p style="top:699.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">in conscious and freely moving rats and its brain </span></p>
<p style="top:710.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">regional distribution. </span><i><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Agr Food Chem</span></i><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2007; 55: </span></p>
<p style="top:721.7pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">1517&#x2013;1524.</span></p>
<p style="top:701.2pt;left:500.0pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">Visit SAGE journals online </span></p>
<p style="top:709.7pt;left:500.0pt;line-height:6.5pt"><span style="font-family:Times New Roman,serif;font-size:6.5pt">http://msj.sagepub.com</span></p>
<p style="top:722.6pt;left:506.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt"> SAGE journals</span></p>

</div>
